PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-11-20

AUTHORS

Ji Soo Lee, Partha Mukhopadhyay, Csaba Matyas, Eszter Trojnar, Janos Paloczi, Yuan Ru Yang, Brandon A. Blank, Cody Savage, Alexander V. Sorokin, Nehal N. Mehta, Janaina C. M. Vendruscolo, George F. Koob, Leandro F. Vendruscolo, Pal Pacher, Falk W. Lohoff

ABSTRACT

Alcoholic liver disease (ALD) causes significant morbidity and mortality, and pharmacological treatment options are limited. In this study, we evaluated the PCSK9 inhibitor alirocumab, a monoclonal antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the treatment of ALD using a rat model of chronic alcohol exposure. Alirocumab (50 mg/kg) or vehicle was administered weekly for 6 weeks to rats receiving a 12% alcohol liquid diet or an isocaloric control diet. At the end of the alcohol exposure protocol, serum and liver samples were obtained for molecular characterization and histopathological analysis. PCSK9 inhibition with alirocumab attenuated alcohol-induced hepatic triglyceride accumulation through regulation of lipid metabolism (mRNA expression of modulators of fatty acid synthesis (FAS) and catabolism (PPARα and CPT1)), hepatocellular injury (ALT), hepatic inflammation (mRNA expression of pro-inflammatory cytokines/chemokines (TNFa, IL-1β, IL-22, IL-33, IL-17α, IL-2, MIP-2, and MCP-1), and neutrophil infiltration (myeloperoxidase staining)). Alirocumab treatment also attenuated alcohol-induced PCSK9 mRNA elevation and upregulated LDL-receptor (LDL-R) via modulation of the transcription factors (SREBP-1, SREBP-2, and E2F1) in liver. We demonstrated that chronic anti-PCSK9 treatment using the monoclonal antibody alirocumab attenuated alcohol-induced steatohepatitis in the rat model. Given the large unmet clinical need for effective and novel treatments for ALD, anti-PCSK9 treatment with the monoclonal antibody that spares liver metabolism is a viable new therapeutic possibility. Future studies are needed to elucidate the exact role of PCSK9 in ALD and alcohol use disorder (AUD) and to evaluate efficacy and safety of anti-PCSK9 treatment in clinical populations with ALD/AUD. More... »

PAGES

17167

References to SciGraph publications

  • 2013-02-28. Mouse model of chronic and binge ethanol feeding (the NIAAA model) in NATURE PROTOCOLS
  • 2005-01-16. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 in NATURE GENETICS
  • 2013-01-08. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets in NUTRITION & METABOLISM
  • 2015-03-17. Alcoholic liver disease: mechanisms of injury and targeted treatment in NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
  • 2018-03-10. Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation in CURRENT ATHEROSCLEROSIS REPORTS
  • 2018-02-02. PCSK9 induces a pro-inflammatory response in macrophages in SCIENTIFIC REPORTS
  • 2014-01-07. Liver transplantation for alcoholic liver disease in NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
  • 2018-08-16. Alcoholic liver disease in NATURE REVIEWS DISEASE PRIMERS
  • 2003-05-05. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia in NATURE GENETICS
  • 2017-09-21. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury in SCIENTIFIC REPORTS
  • 2016-04-01. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia in ENDOCRINE
  • 2017-08-29. Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder in MOLECULAR PSYCHIATRY
  • 2017-02-07. PCSK9 targets important for lipid metabolism in CLINICAL RESEARCH IN CARDIOLOGY SUPPLEMENTS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/s41598-019-53603-6

    DOI

    http://dx.doi.org/10.1038/s41598-019-53603-6

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1122749316

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/31748600


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1101", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Biochemistry and Metabolomics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Alcoholism", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cholesterol, LDL", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Models, Animal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ethanol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fatty Liver", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hypolipidemic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lipid Metabolism", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Lipogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Liver Diseases, Alcoholic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proprotein Convertase 9", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats, Sprague-Dawley", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, LDL", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transcription Factors", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lee", 
            "givenName": "Ji Soo", 
            "id": "sg:person.016500570452.60", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016500570452.60"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mukhopadhyay", 
            "givenName": "Partha", 
            "id": "sg:person.0607275541.53", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607275541.53"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Matyas", 
            "givenName": "Csaba", 
            "id": "sg:person.01063426430.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063426430.82"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Trojnar", 
            "givenName": "Eszter", 
            "id": "sg:person.0655632471.80", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655632471.80"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Paloczi", 
            "givenName": "Janos", 
            "id": "sg:person.0666154643.86", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666154643.86"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Yang", 
            "givenName": "Yuan Ru", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420090.f", 
              "name": [
                "Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Blank", 
            "givenName": "Brandon A.", 
            "id": "sg:person.011171042073.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011171042073.81"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Savage", 
            "givenName": "Cody", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Lipoprotein Metabolism Section, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.279885.9", 
              "name": [
                "Lipoprotein Metabolism Section, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sorokin", 
            "givenName": "Alexander V.", 
            "id": "sg:person.012615363355.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012615363355.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.279885.9", 
              "name": [
                "Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mehta", 
            "givenName": "Nehal N.", 
            "id": "sg:person.01364247030.02", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364247030.02"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420090.f", 
              "name": [
                "Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vendruscolo", 
            "givenName": "Janaina C. M.", 
            "id": "sg:person.0746427754.44", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746427754.44"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420090.f", 
              "name": [
                "Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Koob", 
            "givenName": "George F.", 
            "id": "sg:person.016101234437.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016101234437.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420090.f", 
              "name": [
                "Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vendruscolo", 
            "givenName": "Leandro F.", 
            "id": "sg:person.01371740155.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371740155.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pacher", 
            "givenName": "Pal", 
            "id": "sg:person.0723772600.74", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723772600.74"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA", 
              "id": "http://www.grid.ac/institutes/grid.420085.b", 
              "name": [
                "Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lohoff", 
            "givenName": "Falk W.", 
            "id": "sg:person.01254441213.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254441213.28"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/ng1509", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032479442", 
              "https://doi.org/10.1038/ng1509"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng1161", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011528564", 
              "https://doi.org/10.1038/ng1161"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-017-10924-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091807467", 
              "https://doi.org/10.1038/s41598-017-10924-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1743-7075-10-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011981736", 
              "https://doi.org/10.1186/1743-7075-10-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11789-017-0085-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1083698661", 
              "https://doi.org/10.1007/s11789-017-0085-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41572-018-0014-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1106154135", 
              "https://doi.org/10.1038/s41572-018-0014-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12020-016-0939-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024921503", 
              "https://doi.org/10.1007/s12020-016-0939-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nprot.2013.032", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014169275", 
              "https://doi.org/10.1038/nprot.2013.032"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrgastro.2015.35", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034993885", 
              "https://doi.org/10.1038/nrgastro.2015.35"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11883-018-0718-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1101408014", 
              "https://doi.org/10.1007/s11883-018-0718-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrgastro.2013.247", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012861335", 
              "https://doi.org/10.1038/nrgastro.2013.247"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-018-20425-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100699194", 
              "https://doi.org/10.1038/s41598-018-20425-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/mp.2017.168", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091377953", 
              "https://doi.org/10.1038/mp.2017.168"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-11-20", 
        "datePublishedReg": "2019-11-20", 
        "description": "Alcoholic liver disease (ALD) causes significant morbidity and mortality, and pharmacological treatment options are limited. In this study, we evaluated the PCSK9 inhibitor alirocumab, a monoclonal antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the treatment of ALD using a rat model of chronic alcohol exposure. Alirocumab (50\u2009mg/kg) or vehicle was administered weekly for 6 weeks to rats receiving a 12% alcohol liquid diet or an isocaloric control diet. At the end of the alcohol exposure protocol, serum and liver samples were obtained for molecular characterization and histopathological analysis. PCSK9 inhibition with alirocumab attenuated alcohol-induced hepatic triglyceride accumulation through regulation of lipid metabolism (mRNA expression of modulators of fatty acid synthesis (FAS) and catabolism (PPAR\u03b1 and CPT1)), hepatocellular injury (ALT), hepatic inflammation (mRNA expression of pro-inflammatory cytokines/chemokines (TNFa, IL-1\u03b2, IL-22, IL-33, IL-17\u03b1, IL-2, MIP-2, and MCP-1), and neutrophil infiltration (myeloperoxidase staining)). Alirocumab treatment also attenuated alcohol-induced PCSK9 mRNA elevation and upregulated LDL-receptor (LDL-R) via modulation of the transcription factors (SREBP-1, SREBP-2, and E2F1) in liver. We demonstrated that chronic anti-PCSK9 treatment using the monoclonal antibody alirocumab attenuated alcohol-induced steatohepatitis in the rat model. Given the large unmet clinical need for effective and novel treatments for ALD, anti-PCSK9 treatment with the monoclonal antibody that spares liver metabolism is a viable new therapeutic possibility. Future studies are needed to elucidate the exact role of PCSK9 in ALD and alcohol use disorder (AUD) and to evaluate efficacy and safety of anti-PCSK9 treatment in clinical populations with ALD/AUD.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/s41598-019-53603-6", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.4730391", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2722655", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1045337", 
            "issn": [
              "2045-2322"
            ], 
            "name": "Scientific Reports", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "9"
          }
        ], 
        "keywords": [
          "alcoholic liver disease", 
          "alcohol use disorder", 
          "PCSK9 inhibition", 
          "liver disease", 
          "rat model", 
          "treatment of ALD", 
          "low-density lipoprotein cholesterol", 
          "large unmet clinical need", 
          "monoclonal antibodies", 
          "PCSK9 inhibitor alirocumab", 
          "alcohol-induced steatohepatitis", 
          "pharmacological treatment options", 
          "chronic alcohol exposure", 
          "alcohol liquid diet", 
          "isocaloric control diet", 
          "hepatic triglyceride accumulation", 
          "novel therapeutic target", 
          "unmet clinical need", 
          "new therapeutic possibilities", 
          "alirocumab treatment", 
          "lipoprotein cholesterol", 
          "hepatic inflammation", 
          "significant morbidity", 
          "hepatocellular injury", 
          "treatment options", 
          "alcohol exposure", 
          "liquid diet", 
          "histopathological analysis", 
          "use disorders", 
          "therapeutic target", 
          "triglyceride accumulation", 
          "novel treatments", 
          "liver metabolism", 
          "therapeutic possibilities", 
          "lipid metabolism", 
          "exposure protocol", 
          "mRNA elevation", 
          "control diet", 
          "clinical need", 
          "liver samples", 
          "exact role", 
          "clinical populations", 
          "alirocumab", 
          "treatment", 
          "disease", 
          "antibodies", 
          "future studies", 
          "diet", 
          "inhibition", 
          "metabolism", 
          "steatohepatitis", 
          "morbidity", 
          "molecular characterization", 
          "inflammation", 
          "injury", 
          "transcription factors", 
          "mortality", 
          "rats", 
          "PCSK9", 
          "cholesterol", 
          "liver", 
          "weeks", 
          "serum", 
          "disorders", 
          "efficacy", 
          "study", 
          "exposure", 
          "elevation", 
          "safety", 
          "options", 
          "population", 
          "modulation", 
          "target", 
          "factors", 
          "role", 
          "protocol", 
          "accumulation", 
          "regulation", 
          "need", 
          "samples", 
          "end", 
          "analysis", 
          "model", 
          "possibility", 
          "characterization", 
          "vehicles", 
          "inhibitor alirocumab", 
          "alcohol exposure protocol", 
          "alirocumab attenuated alcohol-induced hepatic triglyceride accumulation", 
          "attenuated alcohol-induced hepatic triglyceride accumulation", 
          "alcohol-induced hepatic triglyceride accumulation", 
          "alcohol-induced PCSK9 mRNA elevation", 
          "PCSK9 mRNA elevation", 
          "chronic anti-PCSK9 treatment", 
          "anti-PCSK9 treatment", 
          "monoclonal antibody alirocumab attenuated alcohol-induced steatohepatitis", 
          "antibody alirocumab attenuated alcohol-induced steatohepatitis", 
          "alirocumab attenuated alcohol-induced steatohepatitis", 
          "attenuated alcohol-induced steatohepatitis", 
          "viable new therapeutic possibility", 
          "ALD/AUD"
        ], 
        "name": "PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease", 
        "pagination": "17167", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1122749316"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/s41598-019-53603-6"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "31748600"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/s41598-019-53603-6", 
          "https://app.dimensions.ai/details/publication/pub.1122749316"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-01-01T18:52", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_817.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/s41598-019-53603-6"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41598-019-53603-6'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41598-019-53603-6'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41598-019-53603-6'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41598-019-53603-6'


     

    This table displays all metadata directly associated to this object as RDF triples.

    396 TRIPLES      22 PREDICATES      158 URIs      137 LITERALS      25 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/s41598-019-53603-6 schema:about N363b9342a2b14392ae6edd447fea466e
    2 N423d5217358a4e3d815610a1901dc4e8
    3 N53b9659ad0f045fc90402e05b52b2ade
    4 N56988d8f1a0e47178748d23446d54743
    5 N5c049fcdaf344b418dea51444a0bf478
    6 N75e2ace2bb7645ec938c29a926eb15ae
    7 N941b14fd37d94ebe8315c44803dde8af
    8 Na3b137ee93d54b1bab1735cf8f4390c0
    9 Nb6c9b03925854668990cb5b196beb8f3
    10 Nbcaa58392f6045278c7423eeff4c9aa0
    11 Nc177c62622474def881314eceaf9d285
    12 Nccb65f2ff8f7422d8027ee4a13f1a752
    13 Nce4e6a78a99f413aa27ea31ad16e74f7
    14 Nd7f3fff3f3364c339802f4efce002785
    15 Nde70708d8e834a93a0b0718996e7e27e
    16 Neb5580ed59de43c5a6eb8a4b07fc47fa
    17 Nf6f3118db4914a218957e16a222024e9
    18 Nfb73a88ebf034800a20b8de7c62ccf59
    19 anzsrc-for:11
    20 anzsrc-for:1101
    21 schema:author N13446836b49445c4baa102e036adcd2b
    22 schema:citation sg:pub.10.1007/s11789-017-0085-0
    23 sg:pub.10.1007/s11883-018-0718-x
    24 sg:pub.10.1007/s12020-016-0939-0
    25 sg:pub.10.1038/mp.2017.168
    26 sg:pub.10.1038/ng1161
    27 sg:pub.10.1038/ng1509
    28 sg:pub.10.1038/nprot.2013.032
    29 sg:pub.10.1038/nrgastro.2013.247
    30 sg:pub.10.1038/nrgastro.2015.35
    31 sg:pub.10.1038/s41572-018-0014-7
    32 sg:pub.10.1038/s41598-017-10924-8
    33 sg:pub.10.1038/s41598-018-20425-x
    34 sg:pub.10.1186/1743-7075-10-4
    35 schema:datePublished 2019-11-20
    36 schema:datePublishedReg 2019-11-20
    37 schema:description Alcoholic liver disease (ALD) causes significant morbidity and mortality, and pharmacological treatment options are limited. In this study, we evaluated the PCSK9 inhibitor alirocumab, a monoclonal antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the treatment of ALD using a rat model of chronic alcohol exposure. Alirocumab (50 mg/kg) or vehicle was administered weekly for 6 weeks to rats receiving a 12% alcohol liquid diet or an isocaloric control diet. At the end of the alcohol exposure protocol, serum and liver samples were obtained for molecular characterization and histopathological analysis. PCSK9 inhibition with alirocumab attenuated alcohol-induced hepatic triglyceride accumulation through regulation of lipid metabolism (mRNA expression of modulators of fatty acid synthesis (FAS) and catabolism (PPARα and CPT1)), hepatocellular injury (ALT), hepatic inflammation (mRNA expression of pro-inflammatory cytokines/chemokines (TNFa, IL-1β, IL-22, IL-33, IL-17α, IL-2, MIP-2, and MCP-1), and neutrophil infiltration (myeloperoxidase staining)). Alirocumab treatment also attenuated alcohol-induced PCSK9 mRNA elevation and upregulated LDL-receptor (LDL-R) via modulation of the transcription factors (SREBP-1, SREBP-2, and E2F1) in liver. We demonstrated that chronic anti-PCSK9 treatment using the monoclonal antibody alirocumab attenuated alcohol-induced steatohepatitis in the rat model. Given the large unmet clinical need for effective and novel treatments for ALD, anti-PCSK9 treatment with the monoclonal antibody that spares liver metabolism is a viable new therapeutic possibility. Future studies are needed to elucidate the exact role of PCSK9 in ALD and alcohol use disorder (AUD) and to evaluate efficacy and safety of anti-PCSK9 treatment in clinical populations with ALD/AUD.
    38 schema:genre article
    39 schema:inLanguage en
    40 schema:isAccessibleForFree true
    41 schema:isPartOf N479336b3652d464f98b43e5188be7f34
    42 Nd637f0f6768646559fe4fb85de4869bd
    43 sg:journal.1045337
    44 schema:keywords ALD/AUD
    45 PCSK9
    46 PCSK9 inhibition
    47 PCSK9 inhibitor alirocumab
    48 PCSK9 mRNA elevation
    49 accumulation
    50 alcohol exposure
    51 alcohol exposure protocol
    52 alcohol liquid diet
    53 alcohol use disorder
    54 alcohol-induced PCSK9 mRNA elevation
    55 alcohol-induced hepatic triglyceride accumulation
    56 alcohol-induced steatohepatitis
    57 alcoholic liver disease
    58 alirocumab
    59 alirocumab attenuated alcohol-induced hepatic triglyceride accumulation
    60 alirocumab attenuated alcohol-induced steatohepatitis
    61 alirocumab treatment
    62 analysis
    63 anti-PCSK9 treatment
    64 antibodies
    65 antibody alirocumab attenuated alcohol-induced steatohepatitis
    66 attenuated alcohol-induced hepatic triglyceride accumulation
    67 attenuated alcohol-induced steatohepatitis
    68 characterization
    69 cholesterol
    70 chronic alcohol exposure
    71 chronic anti-PCSK9 treatment
    72 clinical need
    73 clinical populations
    74 control diet
    75 diet
    76 disease
    77 disorders
    78 efficacy
    79 elevation
    80 end
    81 exact role
    82 exposure
    83 exposure protocol
    84 factors
    85 future studies
    86 hepatic inflammation
    87 hepatic triglyceride accumulation
    88 hepatocellular injury
    89 histopathological analysis
    90 inflammation
    91 inhibition
    92 inhibitor alirocumab
    93 injury
    94 isocaloric control diet
    95 large unmet clinical need
    96 lipid metabolism
    97 lipoprotein cholesterol
    98 liquid diet
    99 liver
    100 liver disease
    101 liver metabolism
    102 liver samples
    103 low-density lipoprotein cholesterol
    104 mRNA elevation
    105 metabolism
    106 model
    107 modulation
    108 molecular characterization
    109 monoclonal antibodies
    110 monoclonal antibody alirocumab attenuated alcohol-induced steatohepatitis
    111 morbidity
    112 mortality
    113 need
    114 new therapeutic possibilities
    115 novel therapeutic target
    116 novel treatments
    117 options
    118 pharmacological treatment options
    119 population
    120 possibility
    121 protocol
    122 rat model
    123 rats
    124 regulation
    125 role
    126 safety
    127 samples
    128 serum
    129 significant morbidity
    130 steatohepatitis
    131 study
    132 target
    133 therapeutic possibilities
    134 therapeutic target
    135 transcription factors
    136 treatment
    137 treatment of ALD
    138 treatment options
    139 triglyceride accumulation
    140 unmet clinical need
    141 use disorders
    142 vehicles
    143 viable new therapeutic possibility
    144 weeks
    145 schema:name PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease
    146 schema:pagination 17167
    147 schema:productId N1f6876ede2c5446586f107475e40fedc
    148 Nb2dafb75e2d44af78ad9be2579ed66bc
    149 Ncd5b40dcb8714dd3bc8ed9eee0eecdd1
    150 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122749316
    151 https://doi.org/10.1038/s41598-019-53603-6
    152 schema:sdDatePublished 2022-01-01T18:52
    153 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    154 schema:sdPublisher N835e7aa8fdc544d1b4f99dd1ed8aad02
    155 schema:url https://doi.org/10.1038/s41598-019-53603-6
    156 sgo:license sg:explorer/license/
    157 sgo:sdDataset articles
    158 rdf:type schema:ScholarlyArticle
    159 N011f2123674d4f78941d341f47e877dd rdf:first sg:person.01063426430.82
    160 rdf:rest N39fd8764bdb445038df98c2fc0991485
    161 N13446836b49445c4baa102e036adcd2b rdf:first sg:person.016500570452.60
    162 rdf:rest Nb0dde082bee647ef821ffb2832b0bf52
    163 N168a1b967f5242958c8155e9dbcf363f rdf:first sg:person.0746427754.44
    164 rdf:rest N3c19c5eb08fd41e89f8ad7daa15738a9
    165 N1f6876ede2c5446586f107475e40fedc schema:name dimensions_id
    166 schema:value pub.1122749316
    167 rdf:type schema:PropertyValue
    168 N2d6853c5a2244ab4bc500b735d131f81 schema:affiliation grid-institutes:grid.420085.b
    169 schema:familyName Yang
    170 schema:givenName Yuan Ru
    171 rdf:type schema:Person
    172 N363b9342a2b14392ae6edd447fea466e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Animals
    174 rdf:type schema:DefinedTerm
    175 N39fd8764bdb445038df98c2fc0991485 rdf:first sg:person.0655632471.80
    176 rdf:rest N5b41b86ad3de4b92b8b9f5b731027e3c
    177 N3c19c5eb08fd41e89f8ad7daa15738a9 rdf:first sg:person.016101234437.45
    178 rdf:rest Nb6a4b26641974af0951d4aaf06749f08
    179 N40c2a576e04f4eb59de862aaa06f8ef8 rdf:first sg:person.01364247030.02
    180 rdf:rest N168a1b967f5242958c8155e9dbcf363f
    181 N423d5217358a4e3d815610a1901dc4e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    182 schema:name Transcription Factors
    183 rdf:type schema:DefinedTerm
    184 N479336b3652d464f98b43e5188be7f34 schema:issueNumber 1
    185 rdf:type schema:PublicationIssue
    186 N53b9659ad0f045fc90402e05b52b2ade schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    187 schema:name Proprotein Convertase 9
    188 rdf:type schema:DefinedTerm
    189 N56988d8f1a0e47178748d23446d54743 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name Ethanol
    191 rdf:type schema:DefinedTerm
    192 N5b41b86ad3de4b92b8b9f5b731027e3c rdf:first sg:person.0666154643.86
    193 rdf:rest N7c62905eda2d42df843e525aec80bbf2
    194 N5c049fcdaf344b418dea51444a0bf478 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    195 schema:name Liver Diseases, Alcoholic
    196 rdf:type schema:DefinedTerm
    197 N75e2ace2bb7645ec938c29a926eb15ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    198 schema:name Male
    199 rdf:type schema:DefinedTerm
    200 N7a182e9e436b4a92a53e7d6960ebf750 rdf:first sg:person.011171042073.81
    201 rdf:rest Ne8b267f22b86441aacc48e236dc4a346
    202 N7c62905eda2d42df843e525aec80bbf2 rdf:first N2d6853c5a2244ab4bc500b735d131f81
    203 rdf:rest N7a182e9e436b4a92a53e7d6960ebf750
    204 N835e7aa8fdc544d1b4f99dd1ed8aad02 schema:name Springer Nature - SN SciGraph project
    205 rdf:type schema:Organization
    206 N941b14fd37d94ebe8315c44803dde8af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    207 schema:name Receptors, LDL
    208 rdf:type schema:DefinedTerm
    209 N9ee8bb258a6545be8bb625c4cfaf0a67 rdf:first sg:person.01254441213.28
    210 rdf:rest rdf:nil
    211 Na3b137ee93d54b1bab1735cf8f4390c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    212 schema:name Hypolipidemic Agents
    213 rdf:type schema:DefinedTerm
    214 Nb0dde082bee647ef821ffb2832b0bf52 rdf:first sg:person.0607275541.53
    215 rdf:rest N011f2123674d4f78941d341f47e877dd
    216 Nb2dafb75e2d44af78ad9be2579ed66bc schema:name doi
    217 schema:value 10.1038/s41598-019-53603-6
    218 rdf:type schema:PropertyValue
    219 Nb6a4b26641974af0951d4aaf06749f08 rdf:first sg:person.01371740155.29
    220 rdf:rest Ndf14f8b8795547aabef027965fe70a4c
    221 Nb6c9b03925854668990cb5b196beb8f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    222 schema:name Rats, Sprague-Dawley
    223 rdf:type schema:DefinedTerm
    224 Nbcaa58392f6045278c7423eeff4c9aa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    225 schema:name Cholesterol, LDL
    226 rdf:type schema:DefinedTerm
    227 Nc177c62622474def881314eceaf9d285 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    228 schema:name Alcoholism
    229 rdf:type schema:DefinedTerm
    230 Nc6d4fd21e1a64baca7c8acf1b0de3fb0 schema:affiliation grid-institutes:grid.420085.b
    231 schema:familyName Savage
    232 schema:givenName Cody
    233 rdf:type schema:Person
    234 Nccb65f2ff8f7422d8027ee4a13f1a752 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    235 schema:name Antibodies, Monoclonal, Humanized
    236 rdf:type schema:DefinedTerm
    237 Ncd5b40dcb8714dd3bc8ed9eee0eecdd1 schema:name pubmed_id
    238 schema:value 31748600
    239 rdf:type schema:PropertyValue
    240 Nce4e6a78a99f413aa27ea31ad16e74f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    241 schema:name Disease Models, Animal
    242 rdf:type schema:DefinedTerm
    243 Nd637f0f6768646559fe4fb85de4869bd schema:volumeNumber 9
    244 rdf:type schema:PublicationVolume
    245 Nd7f3fff3f3364c339802f4efce002785 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    246 schema:name Liver
    247 rdf:type schema:DefinedTerm
    248 Nde70708d8e834a93a0b0718996e7e27e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    249 schema:name Rats
    250 rdf:type schema:DefinedTerm
    251 Ndf14f8b8795547aabef027965fe70a4c rdf:first sg:person.0723772600.74
    252 rdf:rest N9ee8bb258a6545be8bb625c4cfaf0a67
    253 Ne719c35300244ee79d0d98b03cc76e3e rdf:first sg:person.012615363355.13
    254 rdf:rest N40c2a576e04f4eb59de862aaa06f8ef8
    255 Ne8b267f22b86441aacc48e236dc4a346 rdf:first Nc6d4fd21e1a64baca7c8acf1b0de3fb0
    256 rdf:rest Ne719c35300244ee79d0d98b03cc76e3e
    257 Neb5580ed59de43c5a6eb8a4b07fc47fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    258 schema:name Lipogenesis
    259 rdf:type schema:DefinedTerm
    260 Nf6f3118db4914a218957e16a222024e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    261 schema:name Lipid Metabolism
    262 rdf:type schema:DefinedTerm
    263 Nfb73a88ebf034800a20b8de7c62ccf59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    264 schema:name Fatty Liver
    265 rdf:type schema:DefinedTerm
    266 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    267 schema:name Medical and Health Sciences
    268 rdf:type schema:DefinedTerm
    269 anzsrc-for:1101 schema:inDefinedTermSet anzsrc-for:
    270 schema:name Medical Biochemistry and Metabolomics
    271 rdf:type schema:DefinedTerm
    272 sg:grant.2722655 http://pending.schema.org/fundedItem sg:pub.10.1038/s41598-019-53603-6
    273 rdf:type schema:MonetaryGrant
    274 sg:grant.4730391 http://pending.schema.org/fundedItem sg:pub.10.1038/s41598-019-53603-6
    275 rdf:type schema:MonetaryGrant
    276 sg:journal.1045337 schema:issn 2045-2322
    277 schema:name Scientific Reports
    278 schema:publisher Springer Nature
    279 rdf:type schema:Periodical
    280 sg:person.01063426430.82 schema:affiliation grid-institutes:grid.420085.b
    281 schema:familyName Matyas
    282 schema:givenName Csaba
    283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063426430.82
    284 rdf:type schema:Person
    285 sg:person.011171042073.81 schema:affiliation grid-institutes:grid.420090.f
    286 schema:familyName Blank
    287 schema:givenName Brandon A.
    288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011171042073.81
    289 rdf:type schema:Person
    290 sg:person.01254441213.28 schema:affiliation grid-institutes:grid.420085.b
    291 schema:familyName Lohoff
    292 schema:givenName Falk W.
    293 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254441213.28
    294 rdf:type schema:Person
    295 sg:person.012615363355.13 schema:affiliation grid-institutes:grid.279885.9
    296 schema:familyName Sorokin
    297 schema:givenName Alexander V.
    298 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012615363355.13
    299 rdf:type schema:Person
    300 sg:person.01364247030.02 schema:affiliation grid-institutes:grid.279885.9
    301 schema:familyName Mehta
    302 schema:givenName Nehal N.
    303 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364247030.02
    304 rdf:type schema:Person
    305 sg:person.01371740155.29 schema:affiliation grid-institutes:grid.420090.f
    306 schema:familyName Vendruscolo
    307 schema:givenName Leandro F.
    308 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371740155.29
    309 rdf:type schema:Person
    310 sg:person.016101234437.45 schema:affiliation grid-institutes:grid.420090.f
    311 schema:familyName Koob
    312 schema:givenName George F.
    313 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016101234437.45
    314 rdf:type schema:Person
    315 sg:person.016500570452.60 schema:affiliation grid-institutes:grid.420085.b
    316 schema:familyName Lee
    317 schema:givenName Ji Soo
    318 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016500570452.60
    319 rdf:type schema:Person
    320 sg:person.0607275541.53 schema:affiliation grid-institutes:grid.420085.b
    321 schema:familyName Mukhopadhyay
    322 schema:givenName Partha
    323 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607275541.53
    324 rdf:type schema:Person
    325 sg:person.0655632471.80 schema:affiliation grid-institutes:grid.420085.b
    326 schema:familyName Trojnar
    327 schema:givenName Eszter
    328 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655632471.80
    329 rdf:type schema:Person
    330 sg:person.0666154643.86 schema:affiliation grid-institutes:grid.420085.b
    331 schema:familyName Paloczi
    332 schema:givenName Janos
    333 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0666154643.86
    334 rdf:type schema:Person
    335 sg:person.0723772600.74 schema:affiliation grid-institutes:grid.420085.b
    336 schema:familyName Pacher
    337 schema:givenName Pal
    338 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723772600.74
    339 rdf:type schema:Person
    340 sg:person.0746427754.44 schema:affiliation grid-institutes:grid.420090.f
    341 schema:familyName Vendruscolo
    342 schema:givenName Janaina C. M.
    343 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746427754.44
    344 rdf:type schema:Person
    345 sg:pub.10.1007/s11789-017-0085-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083698661
    346 https://doi.org/10.1007/s11789-017-0085-0
    347 rdf:type schema:CreativeWork
    348 sg:pub.10.1007/s11883-018-0718-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1101408014
    349 https://doi.org/10.1007/s11883-018-0718-x
    350 rdf:type schema:CreativeWork
    351 sg:pub.10.1007/s12020-016-0939-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024921503
    352 https://doi.org/10.1007/s12020-016-0939-0
    353 rdf:type schema:CreativeWork
    354 sg:pub.10.1038/mp.2017.168 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091377953
    355 https://doi.org/10.1038/mp.2017.168
    356 rdf:type schema:CreativeWork
    357 sg:pub.10.1038/ng1161 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011528564
    358 https://doi.org/10.1038/ng1161
    359 rdf:type schema:CreativeWork
    360 sg:pub.10.1038/ng1509 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032479442
    361 https://doi.org/10.1038/ng1509
    362 rdf:type schema:CreativeWork
    363 sg:pub.10.1038/nprot.2013.032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014169275
    364 https://doi.org/10.1038/nprot.2013.032
    365 rdf:type schema:CreativeWork
    366 sg:pub.10.1038/nrgastro.2013.247 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012861335
    367 https://doi.org/10.1038/nrgastro.2013.247
    368 rdf:type schema:CreativeWork
    369 sg:pub.10.1038/nrgastro.2015.35 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034993885
    370 https://doi.org/10.1038/nrgastro.2015.35
    371 rdf:type schema:CreativeWork
    372 sg:pub.10.1038/s41572-018-0014-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106154135
    373 https://doi.org/10.1038/s41572-018-0014-7
    374 rdf:type schema:CreativeWork
    375 sg:pub.10.1038/s41598-017-10924-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091807467
    376 https://doi.org/10.1038/s41598-017-10924-8
    377 rdf:type schema:CreativeWork
    378 sg:pub.10.1038/s41598-018-20425-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1100699194
    379 https://doi.org/10.1038/s41598-018-20425-x
    380 rdf:type schema:CreativeWork
    381 sg:pub.10.1186/1743-7075-10-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011981736
    382 https://doi.org/10.1186/1743-7075-10-4
    383 rdf:type schema:CreativeWork
    384 grid-institutes:grid.279885.9 schema:alternateName Lipoprotein Metabolism Section, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD USA
    385 Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD USA
    386 schema:name Lipoprotein Metabolism Section, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD USA
    387 Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD USA
    388 rdf:type schema:Organization
    389 grid-institutes:grid.420085.b schema:alternateName Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA
    390 Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA
    391 schema:name Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA
    392 Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD USA
    393 rdf:type schema:Organization
    394 grid-institutes:grid.420090.f schema:alternateName Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA
    395 schema:name Neurobiology of Addiction Section, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD USA
    396 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...